amlodipine has been researched along with eplerenone in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 7 (43.75) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB | 1 |
| Akhras, KS; Anderson, R; Bittman, RM; Hollenberg, NK; Krause, SL; Williams, GH | 1 |
| Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F | 1 |
| Burgess, E | 1 |
| Laustsen, G; Wimmett, L | 1 |
| Du, J; Fan, YY; Hitomi, H; Kimura, S; Kiyomoto, H; Kohno, M; Kong, CZ; Nakano, D; Nishiyama, A; Noma, T | 1 |
| Chen, C; Ding, G; Hu, F; Liang, W; Ren, Z; Shi, J; Singhal, PC; van Goor, H | 1 |
| Inagaki, K; Kumagai, I; Makino, H; Miyoshi, T; Nakamura, E; Ogura, T; Otsuka, F; Suzuki, J; Tanabe, K; Tsukamoto, N | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yasuda, O | 1 |
| Funder, JW | 1 |
| Adler, GK; Green, JAEM; Hornik, ES; Koefoed, AW; Stone, IB; Williams, GH; Williams, JS | 1 |
| Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC | 1 |
| Adams-Huet, B; Arbique, D; Iwamoto, G; Lodhi, H; Mitchell, JH; Mizuno, M; Peri-Okonny, PA; Smith, S; Velasco, A; Vongpatanasin, W; Wang, Z | 1 |
3 review(s) available for amlodipine and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Eplerenone in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Enalapril; Eplerenone; Humans; Hypertension; Spironolactone | 2004 |
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator Agents; Cardiovascular Agents; Drug Approval; Drug Combinations; Duloxetine Hydrochloride; Eplerenone; Estradiol; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Agents; Heptanoic Acids; Humans; Ketolides; Male; Memantine; Osteoporosis, Postmenopausal; Pyrroles; Rifamycins; Rifaximin; Scopolamine Derivatives; Spironolactone; Thiophenes; Tiotropium Bromide; United States | 2005 |
5 trial(s) available for amlodipine and eplerenone
| Article | Year |
|---|---|
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Creatinine; Diarrhea; Double-Blind Method; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nausea; Pulsatile Flow; Spironolactone; Systole; Treatment Outcome | 2003 |
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Topics: Aged; Amlodipine; Analysis of Variance; Calcium Channel Blockers; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Quality of Life; Renin-Angiotensin System; Spironolactone; Statistics, Nonparametric; Treatment Outcome | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Enalapril; Eplerenone; Female; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myocardium; Potassium; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2003 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Binding Proteins; Clinical Trials as Topic; Eplerenone; Genetic Predisposition to Disease; Humans; Hypertension; Male; Membrane Proteins; Mice; Middle Aged; Mineralocorticoid Receptor Antagonists; Nerve Tissue Proteins; Polymorphism, Single Nucleotide; Receptors, Mineralocorticoid; Young Adult | 2021 |
Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans.
Topics: Amlodipine; Animals; Blood Pressure; Cross-Over Studies; Eplerenone; Hand Strength; Humans; Hypertension; Muscle, Skeletal; Rats | 2021 |
8 other study(ies) available for amlodipine and eplerenone
| Article | Year |
|---|---|
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
Topics: Carboxylic Acids; Cytochrome P-450 Enzyme System; Esters; Humans; Hydrolysis; Microsomes; Models, Molecular; Molecular Structure; Prodrugs; Quantum Theory; Signal Transduction | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia; Creatinine; Drug Therapy, Combination; Endothelial Cells; Eplerenone; Fibrosis; Hypertension; Immediate-Early Proteins; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Mineralocorticoid Receptor Antagonists; Podocytes; Protein Serine-Threonine Kinases; Proteinuria; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Sodium Chloride, Dietary; Spironolactone; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats.
Topics: Albuminuria; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzimidazoles; Benzoates; Blotting, Western; Calcium Channel Blockers; Eplerenone; Immunoenzyme Techniques; Kidney Glomerulus; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Podocytes; Proteinuria; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Telmisartan | 2011 |
Effects of eplerenone on nephrotic syndrome in a patient with renovascular hypertension.
Topics: Amlodipine; Antihypertensive Agents; Dihydropyridines; Eplerenone; Humans; Hypertension, Renovascular; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Nephrotic Syndrome; Proteinuria; Radiography; Spironolactone; Treatment Outcome | 2011 |
Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Drug Therapy, Combination; Endothelium, Vascular; Eplerenone; Heart; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Nitric Oxide Synthase Type III; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; Sodium Chloride, Dietary; Spironolactone; Superoxides; Treatment Outcome | 2011 |
Eplerenone, amlodipine and experimental hypertension: one plus one equals three.
Topics: Amlodipine; Animals; Antihypertensive Agents; Eplerenone; Heart; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Spironolactone | 2011 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Small Vessel Diseases; Cerebrovascular Circulation; Dementia, Vascular; Disease Models, Animal; Drug Therapy, Combination; Eplerenone; Heart Disease Risk Factors; Humans; Hyperemia; Hypertension; Losartan; Male; Mice; Microvessels; Potassium Channels, Inwardly Rectifying; Renin-Angiotensin System | 2021 |